<DOC>
	<DOCNO>NCT02999308</DOCNO>
	<brief_summary>In past , due economic medical resource constraint , hemophilia comprehensive care China suboptimal . The BCH data retrospective prospective study reveal 4-6y 6-9y patient severe hemophilia respectively : 45 % 82 % patient suffer joint bleeding , mean AJBR 4.18 4.95 ; 24.2 % 33.3 % AJBR &gt; 10 time , lead arthropathy make quality life heavy affect . Now , development economy medical science China , prophylaxis regimen initiate child hemophilia . Considering difference prophylaxis regimen , frequency joint bleeding reduce significantly , quality life hemophilia kid improve . An assessment score system appropriate validation individualize prophylaxis treatment regimen urgently need . Before , important assess indication hemophilia prophylaxis frequency joint bleeding . But increase evidence show discrepancy real joint damage joint bleeding frequency . The single indicator joint bleeding frequency sufficient evaluate joint status hemophilia child . Under World Health Organization 's ICF guideline , assessment score system select prophylaxis child hemophilia include tool currently available assessment structure/function joint , patient activity patient participation hemophilia healthcare . According ICF WHO , common bleeding part elbow , knee ankle , therefore assessment child hemophilia include evaluation structure , function 6 Index joint , capacity activity capacity participation child . These constitute comprehensive hemophilia evaluation system . In China , exploration optimal individualized prophylaxis regimen urgent , comprehensive evaluation system include joint structure function , body 's activity individual participation , thus may appropriate individualized prophylaxis Chinese child hemophilia .</brief_summary>
	<brief_title>A Clinical Phenotype Based Individualized Prophylaxis Chinese Hemophilia A Children</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<criteria>1 . Severe hemophilia A ( FVIII : C &lt; 2 % ) , 2 . Age 17y 3 . Historical bleeding knee , elbow ankle joint ( ) , 4 . ＞50 EDs irrespective FVIII product , include human coagulate factor recombinant factor VIII 5 . No inhibitor present history/family history , 6 . Ondemand lowdose prophylaxis ( dose per kg.week le Step 1 prophylaxis regimen factor consumption ) 7 . Regular clinical visit accessible data , 8 . Informed consent obtain patient legal guardian enrollment . 1 . Other bleed disorder systemic disorder , n't fit enrollment accord investigator , 2 . FVIII inhibitor development : ＞0.6 BU ( confirm two separate test ) , 3 . Unable follow protocol refuse continue participation .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>7 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>haemophilia</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>child</keyword>
</DOC>